ATAI Life Sciences Files 8-K Report
Ticker: ATAI · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, other-events
TL;DR
ATAI filed an 8-K, something happened, more info needed.
AI Summary
On October 2, 2024, ATAI Life Sciences N.V. filed an 8-K report to disclose other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the report date.
Why It Matters
This filing indicates a material event has occurred for ATAI Life Sciences, requiring public disclosure. Investors should monitor for further details to understand the impact.
Risk Assessment
Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty, necessitating further investigation by investors.
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- October 2, 2024 (date) — Date of earliest event reported
- 001-40493 (other) — Commission File Number
FAQ
What specific event(s) are being reported in this 8-K filing?
The filing is categorized under 'Other Events' but does not provide specific details regarding the nature of the event(s).
When was the earliest event reported in this filing?
The earliest event reported was on October 2, 2024.
What is the Commission File Number for ATAI Life Sciences N.V.?
The Commission File Number is 001-40493.
Where is ATAI Life Sciences N.V.'s principal executive office located?
The principal executive offices are located at Wallstraße 16, 10179 Berlin, Germany.
What is the former name of ATAI Life Sciences N.V. and when did the name change occur?
The former name was ATAI Life Sciences B.V., and the date of the name change was January 15, 2021.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-04 16:02:03
Filing Documents
- ef20036713_8k.htm (8-K) — 26KB
- 0001140361-24-042874.txt ( ) — 161KB
- atai-20241002.xsd (EX-101.SCH) — 4KB
- atai-20241002_lab.xml (EX-101.LAB) — 22KB
- atai-20241002_pre.xml (EX-101.PRE) — 16KB
- ef20036713_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On October 2, 2024, atai Life Sciences N.V. (the "Company") acquired all of the issued and outstanding shares of IntelGenx Corp. ("IGX"), a subsidiary of IntelGenx Technologies Corp. ("IntelGenx") following the approval and vesting order obtained by IGX on September 30, 2024 from the Superior Court of Qubec (Commerical Division) issued in connection with the proceedings instituted pursuant to the Companies' Creditors Arrangement Act. IntelGenx is a novel drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market and is used for the Company's development candidate, VLS-01. The acquisition was structured as a credit bid, whereby the Company agreed that its senior secured debt in IGX was discharged in exchange for IGX shares. No Company equity or cash was exchanged in connection with this transaction.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: October 4, 2024 By: /s/ Florian Brand Name: Florian Brand Title: Co-Chief Executive Officer